bioAffinity Technologies, Inc. — Regulatory Filings 2022

Aug 2, 2022

8-A12B 1 form8-a12b.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

| Delaware (State
or incorporation of organization) | 46-5211056 (IRS
Employer Identification No.) |
| --- | --- |
| 22211
W Interstate 10, Suite 1206 San Antonio, Texas (210)
698-5334 (Address
of Principal Executive Offices) | 78257 (Zip
Code) |

Securities to be registered pursuant to Section 12(b) of the Act:

| Title
of each class to be so registered | Name
of each exchange on which each class is to be registered |
| --- | --- |
| Common
Stock, par value $0.007 | The
Nasdaq Stock Market LLC |
| Tradeable Warrants to
purchase Common Stock | The Nasdaq Stock Market LLC |

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement file number to which this form relates: 333-264463 .

Securities to be registered pursuant to Section 12(g) of the Act: None .

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1. Description of Registrant’s Securities to be Registered.

bioAffinity Technologies, Inc. (the “Company”) hereby incorporates by reference herein the description of its common stock, par value $0.007 (the “Common Stock”), to be registered hereunder, set forth under the heading “Description of Securities—Common Stock” in the Company’s Amendment No. 3 to Form S-1 (File No. 333-264463) , filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), on July 28, 2022, which amended the Company’s initial Registration Statement on Form S-1, originally filed with the Commission on April 25, 2022, as subsequently amended (the “Registration Statement”), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act (each, a “Rule 424(b) Prospectus”), which information shall be deemed to be incorporated herein by reference.

The description of the Tradeable Warrants to purchase Common Stock (the “Tradeable Warrants”) of the Company, to be registered hereunder, is contained in the section titled “Description of Securities—Warrants—Warrants to Be Issued in the Offering” in the Company’s Amendment No. 3 to Form S-1 and any Rule 424(b) Prospectus, which information shall be deemed to be incorporated herein by reference.

Item 2. Exhibits.

Pursuant to the “Instructions as to Exhibits” section of Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2

Field: /Page

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

| Date:
August 2, 2022 | |
| --- | --- |
| By: | /s/
Maria Zannes |
| Name: | Maria
Zannes |
| Title: | President
and Chief Executive Officer |

Field: Page; Sequence: 3; Options: Last

3

Field: /Page